2015
DOI: 10.1167/iovs.15-16990
|View full text |Cite
|
Sign up to set email alerts
|

Systemic Retinaldehyde Treatment Corrects Retinal Oxidative Stress, Rod Dysfunction, and Impaired Visual Performance in Diabetic Mice

Abstract: PURPOSE. Diabetes appears to induce a visual cycle defect because rod dysfunction is correctable with systemic treatment of the visual cycle chromophore 11-cis-retinaldehyde. However, later studies have found no evidence for visual cycle impairment. Here, we further examined whether photoreceptor dysfunction is corrected with 11-cis-retinaldehyde. Because antioxidants correct photoreceptor dysfunction in diabetes, the hypothesis that exogenous visual chromophores have antioxidant activity in the retina of diab… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
32
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 25 publications
(35 citation statements)
references
References 62 publications
(84 reference statements)
3
32
0
Order By: Relevance
“…This is consistent with lack of photoreceptor loss (35) and absence of reports of reduced scotopic ERGs in patients with diabetes. Since other studies have shown attenuated photoreceptor function in ex vivo transretinal recordings from STZ mice (36), our findings may not be universal and restricted to the db/db mouse as a model of type 2 diabetes. It is also possible that compromised rod photoreceptor function in the STZ mouse model is due to known neurotoxic effects of STZ (37) rather than a consequence of diabetes.…”
Section: Discussionmentioning
confidence: 70%
“…This is consistent with lack of photoreceptor loss (35) and absence of reports of reduced scotopic ERGs in patients with diabetes. Since other studies have shown attenuated photoreceptor function in ex vivo transretinal recordings from STZ mice (36), our findings may not be universal and restricted to the db/db mouse as a model of type 2 diabetes. It is also possible that compromised rod photoreceptor function in the STZ mouse model is due to known neurotoxic effects of STZ (37) rather than a consequence of diabetes.…”
Section: Discussionmentioning
confidence: 70%
“…Glaucoma [137] Retinoids Systemically administration reduces retinal OS and correct rod dysfunction. DR [138] Finally, other treatments for retinal dystrophies are based on promoting cytoprotective pathways. As aforementioned, RP is a mendelian rare disease caused by mutation in many genes but increasing evidence in patients and animal models suggests that oxidative stress and inflammation contribute to its pathogenesis irrespective of the causative gene.…”
Section: Amd [132]mentioning
confidence: 99%
“…Potential approaches include the use of light (photobiomodulation) or agents that affect photoreceptors by direct or indirect means, including retinylamine, and agonists and antagonists of G-protein coupled receptors [28] (which are known to be prevalent in photoreceptors). Administration of other retinaldehydes has corrected diabetes-induced photoreceptor dysfunction (including subnormal dark-adapted rod photoresponses, rod-dominated light-stimulated expansion of the subretinal space, and cone-dominated contrast sensitivity), potentially via an antioxidant mechanism [68]. The extent to which the visual cycle contribute to the retinopathy, and the possibility that light-initiated phototransduction or subsequent changes in photoreceptor ion channel activities also might contribute to the molecular processes leading to DR merit further investigation.…”
Section: Future Directionsmentioning
confidence: 99%